Phase 2 Study of TAVT-119 (Amlodipine Besylate) Gel in Patients with Chronic Anal Fissure

Genovéva Filipcsei¹, László Ritter², László Hornok², Áron Altorjay³, Ferenc Ender⁴, Zoltán Tomcsik⁴, Marie Watissée⁵, Elizabeth Manning Duus⁶

¹TAVANTA Therapeutics, Budapest, Hungary; ²National Institute of Mental Health, Neurology and Neurosurgery – Nyírő Gyula Hospital, Department of Proctology, Budapest, Hungary; ³County Hospital Fejér, Szent György Hospital, Fejér Department of Surgery, Budapest, Hungary; ⁴South-Pest Hospital Centre – National Institute for Infectology and Haematology, Department of Surgery, Budapest, Hungary; ⁵WStats Limited, London, UK; ⁶TAVANTA Therapeutics, King of Prussia, PA, USA



Background

First line treatments for anal fissure (AF) include:

- Topical nitrates (limited by headache / tolerability)¹⁻³
- Topical calcium channel blockers (not FDA approved; compounded)1,4
- TAVT-119 is a novel amlodipine formulation in development to treat anal fissure pain

Objectives

 To assess the efficacy, safety, and tolerability of TAVT-119 gel in patients with AF

Methods

Study Design

 Phase 2, 6-week, double-blind, placebo-controlled trial (Part 1), with a 6-week open-label extension (Part 2) Conducted at 3 sites in Hungary (EUDRACT: 2019-000853-30)

Key Eligibility

◆ Part 1: Aged ≥18 years; single, chronic AF (≥6 weeks); moderate to severe anal pain (50–100 mm on a 100 mm visual analog scale [VAS] over past 2 weeks) Part 2: Not completely healed at the end of Part 1

Assessments

Anal pressure (manometry)

#ASCRS23

- Investigator-assessed healing (grade 0 [none], grade 1 [partial], or grade 2 [complete])
- Pain (VAS 0–100 mm; 0 = no pain)
- Bleeding (anal bleeding score [ABS], 2–9; 2 = lowest frequency and amount)
- Complete response (composite of healing [grade 2]) and pain [30% decrease])
- Safety (vitals and treatment-emergent adverse events) (TEAEs))


Analyses

- Changes from baseline in resting anal pressure (primary endpoint at Day 42), anal pain, and bleeding analyzed using mixed model repeated measures
- Secondary endpoints were summarized descriptively
- The responder analyses included number of patients with ≥30% reduction in pain (pre-specified), ≥50% reduction in pain (post hoc), and no anal bleeding (ABS=2; post hoc)
- Interim assessment for conditional powering of primary endpoint when 50% of patients completed Part 1

Results

Study Status/Patients

- Of the 90 planned patients, 51 were randomized between 7 Aug 2019 and 10 Jun 2020 (Figure 1)
- Recruitment was stopped early in Mar 2020 as sites closed due to COVID-19; terminated in Jun 2020 due to interim assessment
- The groups were well-matched demographically (Table 1)



^aA total of 43 patients continued into Part 2 of the study, to all receive TAVT-119 0.2% twice daily (BID) TAVT-119 0.1% gel BID was equivalent to 1 mg amlodipine daily; TAVT-119 0.2% gel BID was equivalent to 2 mg amlodipine daily; all patients received best supportive care during the study

(safety population)							
	Statistic	Placebo (n=16)	TAVT-119 0.1% (n=17)	TAVT-119 0.2% (n=16)	Overall (N=49)		
Sex, male	n (%)	10 (62.5)	11 (64.7)	9 (56.3)	30 (61.2)		
Age (years)	Mean (SD)	46.1 (12.8)	46.5 (13.1)	41.6 (13.8)	44.8 (13.2)		
Race, White	n (%)	16 (100)	17 (100)	16 (100)	49 (100)		
Resting anal pressure (mmHg)	Mean (SD)	100.9 (20.8)	95 (24.2)	101.3 (26.2)	-		
Anal pain intensity (mm)	Mean (SD)	76.2 (23.3)	69.9 (22)	71.8 (25.7)	_		
Total bleeding score	Mean (SD)	5.3 (2)	5.4 (2.1)	5.7 (2.8)	-		
SD, standard deviation							

Efficacy

• At Day 42, there were no significant differences between active treatment and placebo in anal pressure, and no clinically significant differences for complete healing or complete response rates (Table 2)

 However, positive trends were noted for anal pain and bleeding in patients treated with TAVT-119 vs placebo gel (Figures 2A-D)




Table 1. Patient demographics and baseline disease characteristics **Table 2.** Efficacy results at day 42 (ITT population)

	(n=16)	(n=17)	(n=16)
LSM change in anal pressure from baseline, mmHg (95% CI)	-42.3 (-53.6, -31.1)	-43.5ª (-55.3, -31.6)	-36.1ª (-47.0, -25.2)
Complete response, n (%)	4 ^b (26.7)	6 (35.3)	3 (18.8)
Complete healing, n (%)	4 ^b (26.7)	6 (35.3)	3 (18.8)
≥30% reduction in anal pain, n (%)	13 ^b (86.7)	13 (76.5)	14 (87.5)

^aNo significant difference vs placebo. ^bn=15 at Day 42 CI, confidence interval: ITT, intent to treat: LSM, least-squares mean

Safetv

- In Part 1, TAVT-119 was generally well tolerated, with TEAEs in 13 placebo patients (81.3%), and 10 (58.8%) and 11 (68.8%) patients receiving TAVT-119 0.1% and 0.2%, respectively
- There were no serious AEs, and the most common TEAEs are shown in Table 3

Table 3. Most frequent TEAEs (safety population)

Number (%) of patients Placebo (n=16) TAVT-119 0.1% (n=17) TAVT-119 0.2% (n=16) Overall (N=49) Anorectal discomfort 5 (31.3) 1 (5.9) 2 (12.5) 8 (16.3) Constipation 2 (12.5) 2 (11.8) 1 (6.3) 5 (10.2) Oropharyngeal pain 1 (6.3) 2 (11.8) 2 (12.5) 5 (10.2) Diarrhea 3 (18.8) 1 (5.9) 0 4 (8.2) Nasopharyngitis 1 (6.3) 2 (11.8) 0 3 (6.1) Headache 0 2 (11.8) 1 (6.3) 3 (6.1) Hypertension 0 3 (17.6) 0 3 (6.1)					
Constipation 2 (12.5) 2 (11.8) 1 (6.3) 5 (10.2) Oropharyngealpain 1 (6.3) 2 (11.8) 2 (12.5) 5 (10.2) Diarrhea 3 (18.8) 1 (5.9) 0 4 (8.2) Nasopharyngitis 1 (6.3) 2 (11.8) 0 3 (6.1) Headache 0 2 (11.8) 1 (6.3) 3 (6.1)					
Oropharyngeal pain 1 (6.3) 2 (11.8) 2 (12.5) 5 (10.2) Marrhea 3 (18.8) 1 (5.9) 0 4 (8.2) Jasopharyngitis 1 (6.3) 2 (11.8) 0 3 (6.1) Jeadache 0 2 (11.8) 1 (6.3) 3 (6.1)	norectal discomfort	5 (31.3)	1 (5.9)	2 (12.5)	8 (16.3)
Diarrhea 3 (18.8) 1 (5.9) 0 4 (8.2) Jasopharyngitis 1 (6.3) 2 (11.8) 0 3 (6.1) Jeadache 0 2 (11.8) 1 (6.3) 3 (6.1)	Constipation	2 (12.5)	2 (11.8)	1 (6.3)	5 (10.2)
lasopharyngitis 1 (6.3) 2 (11.8) 0 3 (6.1) leadache 0 2 (11.8) 1 (6.3) 3 (6.1))ropharyngeal pain	1 (6.3)	2 (11.8)	2 (12.5)	5 (10.2)
leadache 0 2 (11.8) 1 (6.3) 3 (6.1)	iarrhea	3 (18.8)	1 (5.9)	0	4 (8.2)
	Vasopharyngitis	1 (6.3)	2 (11.8)	0	3 (6.1)
Hypertension 0 3 (17.6) 0 3 (6.1)	leadache	0	2 (11.8)	1 (6.3)	3 (6.1)
	lypertension	0	3 (17.6)	0	3 (6.1)

Study Limitations

Small sample size due to early termination of the study Anal pressure assessed 12 hours post-dose (later than other studies^{5,6}), and may have limited clinical relevance Six weeks may not be long enough to compare effects on healing

Conclusions

TAVT-119 gel was generally well tolerated in AF patients, with the 0.2% strength showing promise in reducing anal pain. Further evaluation of TAVT-119 gel is planned.



ASCRS ANNUAL SCIENTIFIC MEETING

- Davids IS, et al. Dis Colon Rectum, 2023;66(2):190-9 et al. Cochrane Database Syst Rev. 2012:2012(2):CD003431
 - escribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf; accessed 07 March 2023
 - - 6. Jonas M, et al. Dis Colon Rectum. 2002;45:1091-5.

- Shah M. et al. World I Gastroenterol. 2013;19:5645-50.
- Carapeti EA, et al. Gut. 1999:45:719-22.